
Johnson & Johnson
NYSE:JNJ

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
141.217
167.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

Intrinsic Value
The intrinsic value of one
JNJ
stock under the Base Case scenario is
163
USD.
Compared to the current market price of 155.71 USD,
Johnson & Johnson
is
Undervalued by 4%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Johnson & Johnson
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.

Valuation History
Historical valuation for JNJ cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:

Continued legal challenges, especially around talc-based products and opioid-related lawsuits, could result in substantial settlement costs and negatively impact Johnson & Johnson’s reputation and cash flow.
The recent consumer health spinoff (Kenvue) could dilute brand synergies and disrupt revenue diversification, hindering Johnson & Johnson’s ability to leverage cross-segment strengths in marketing and R&D.
Potential patent expirations in the pharmaceutical segment and intensifying generic competition may reduce pricing power, forcing Johnson & Johnson to allocate additional resources to pipeline development and acquisitions.
Its diversified portfolio across pharmaceuticals, medical devices, and consumer health products insulates Johnson & Johnson from downturns in any single category, supporting stable revenue and cash generation.
Robust late-stage pharmaceutical pipeline, particularly in oncology and immunology, could secure new growth avenues and help counterbalance upcoming patent expirations.
The spinoff of Kenvue may allow Johnson & Johnson to focus on higher-margin segments, such as medical devices and pharmaceuticals, improving profitability and operational efficiency over the long term.

Revenue & Expenses Breakdown
Johnson & Johnson
Balance Sheet Decomposition
Johnson & Johnson
Current Assets | 71.6B |
Cash & Short-Term Investments | 38.8B |
Receivables | 16B |
Other Current Assets | 16.8B |
Non-Current Assets | 122.1B |
Long-Term Investments | 773m |
PP&E | 20.9B |
Intangibles | 81.2B |
Other Non-Current Assets | 19.3B |
Current Liabilities | 56.9B |
Accounts Payable | 9.5B |
Accrued Liabilities | 29.2B |
Short-Term Debt | 10.9B |
Other Current Liabilities | 7.2B |
Non-Current Liabilities | 58.7B |
Long-Term Debt | 38.4B |
Other Non-Current Liabilities | 20.3B |
Free Cash Flow Analysis
Johnson & Johnson
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Johnson & Johnson
Revenue
|
89.3B
USD
|
Cost of Revenue
|
-28.3B
USD
|
Gross Profit
|
61.1B
USD
|
Operating Expenses
|
-37.7B
USD
|
Operating Income
|
23.4B
USD
|
Other Expenses
|
-1.6B
USD
|
Net Income
|
21.8B
USD
|
JNJ Profitability Score
Profitability Due Diligence
Johnson & Johnson's profitability score is 68/100. The higher the profitability score, the more profitable the company is.

Score
Johnson & Johnson's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
JNJ Solvency Score
Solvency Due Diligence
Johnson & Johnson's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Score
Johnson & Johnson's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
JNJ Price Targets Summary
Johnson & Johnson
According to Wall Street analysts, the average 1-year price target for
JNJ
is 174.05 USD
with a low forecast of 151.5 USD and a high forecast of 194.25 USD.
Dividends
Current shareholder yield for JNJ is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
JNJ
stock under the Base Case scenario is
163
USD.
Compared to the current market price of 155.71 USD,
Johnson & Johnson
is
Undervalued by 4%.